Shanghai, November 9, 2020-- Haihe Biopharma Co., Ltd. , a leading biotech company focusing on the discovery and development of innovative oncology drugs, and Guangxi Noventi Pharmaceuticals Co., Ltd. (hereinafter referred to as “Noventi”) announced today that the two sides have reached a licensing agreement on Haihe Biopharma’s in-licensed innovative antibiotics, RMX2001. Noventi may carry out the R&D, manufacture and commercialization of RMX2001 in China.

RMX2001 is a second-generation oxazolidinone analogue. Existing data shows that RMX2001 has strong antibacterial activity and can significantly alleviate the adverse reactions of bone marrow suppression of the same class drugs. It has the potential to treat multi-drug resistant tuberculosis. Haihe's subsidiary RMX Biopharma in-licensed the China rights for R&D, manufacture and commercialization of RMX2001 from South Korea, and completed the phase I clinical study in China.

Multidrug-resistant tuberculosis (MDR-TB) refers to tuberculosis in which tuberculosis patients are infected with Mycobacterium tuberculosis in vitro and confirmed that they are resistant to both isoniazid and rifampicin. According to the World Health Organization (WHO) "Global Tuberculosis Report 2020" data, there were approximately 465,000 new rifampicin-resistant tuberculosis cases worldwide in 2019, of which 78% (363,000 cases) were multidrug-resistant tuberculosis. The treatment success rate is only 57%, and the case fatality rate is 15%. India (27%), China (14%) and Russia (8%) are the three countries with the largest global burden of drug-resistant tuberculosis.

Chemotherapy is currently the most important treatment for MDR-TB. Chemotherapy regimens include long-term MDR-TB treatment regimen (referring to an 18-20-month treatment regimen consisting of at least 4 effective anti-tuberculosis drugs) and short-term MDR-TB treatment regimen (treatment course is 9-12 months). Clinically, the safety monitoring and management of anti-tuberculosis drugs should be actively carried out for patients receiving MDR-TB treatment, and the adverse reactions of anti-tuberculosis drugs should be detected and dealt with in time. MDR-TB is difficult to treat. It has a long infectious period with high mortality, high treatment cost, and low cure rate. Therefore, the active R&D of new anti-tuberculosis drugs is of great significance to the control of MDR-TB.

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions. 

Please visit the company website for more information: http://www.haihepharma.com

Noventi Pharma focuses on digestive system diseases and infectious diseases to solve unmet clincial, with the purpose of providing patients with transformative treatments and solving unmet clinical needs. Through the development of innovative and transformative therapies, Noventi aims to treat serious diseases such as intestinal microecological disorders, multi-drug resistant bacterial infections and gastrointestinal tumors. In Noventi’s innovative drug R&D pipeline, Atisamine, the first domestic (the third in the world) small molecule innovative drug for diarrheal irritable bowel syndrome,  is about to complete the phase III clinical trial; the world's first intelligence-assisted diagnosis and treatment system (AI doctor) based on natural language processing (NLP) and functional gastrointestinal medical knowledge base is about to be launched; health products targeting the human microecology have also formed a strategic portfolio. Noventi is meeting patients' medical and healthcare needs from multiple levels and angles. Noventi was jointly established by well-known investors in the biopharmaceutical industry. The series B financing underway was led by Yingke Capital and Tiger Investment.